Descriptors
Documents disponibles dans cette catégorie (122)


Extend search on down-posting(s)
Allgemeine Gynäkologie. Frauenheilkunde und Geburtshilfe in Deutschland / B. Augurzky, in Geburtshilfe und Frauenheilkunde, 69(2009)6 ([06/01/2009])
![]()
[article] Allgemeine Gynäkologie. Frauenheilkunde und Geburtshilfe in Deutschland = Gynecology and Obstetrics in Germany Costs and Revenues : Kosten und Erlöse [printed text] / B. Augurzky,, Author ; S. Krolop, Author ; K. Römer, Author ; Christoph Schwierz, Author ; R. Kreienberg, Author . - 2009 . - 560-563.
Languages : English (eng) German (ger)
in Geburtshilfe und Frauenheilkunde > 69(2009)6 [06/01/2009] . - 560-563
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Costs and Cost Analysis ; Germany ; Gynecology ; Journal Article ; Obstetrics ; Peer ReviewLink for e-copy: https://www.thieme-connect.de/ejournals/toc/gebfra Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2073 [article]Analyse coût-efficacité de la vaccination des garçons contre le virus HPV / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
![]()
Analyse coût-efficacité de la vaccination des garçons contre le virus HPV : Synthèse [printed text] / Nancy Thiry, Author ; Sophie Gerkens, Author ; Justien Cornelis
, Author ; Vicky Jespers
, Author ; Germaine Hanquet, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2019 . - 21 p. : ill., ; A4. - (KCE Reports B. Health Technology Assessment (HTA); 308B) .
ISSN : D/2019/10.273/12 : 0,00
Languages : French (fre)
Descriptors: Indexation
2017-04 ; Costs and Cost Analysis ; Female ; Male ; Papillomavirus Infections ; Papillomavirus Vaccines ; R308 ; Technology Assessment, Biomedical
Classification
QZ 204 Precancerous conditions. Tumor virus infectionsAbstract: Le vaccin contre le papillomavirus humain (HPV) responsable du cancer du col de lutérus est introduit depuis une petite dizaine dannées dans notre pays, mais seules les filles en bénéficient. Or il est désormais établi que ce même virus est également impliqué dans dautres cancers, dont celui de la gorge. Les recommandations ont donc été revues et, dans la plupart des pays occidentaux comme chez nous, il est désormais conseillé de vacciner les garçons aussi. La question de limpact clinique et économique dune telle extension des programmes de vaccination a donc été posée au Centre fédéral dExpertise des Soins de Santé (KCE), qui publie aujourdhui une étude favorable. Contents note: PRÉFACE. 1 -- SYNTHÈSE . 2 -- TABLE DES MATIÈRES. 2 -- 1. CONTEXTE. 4 -- 1.1. LE VIRUS HPV ET LE RISQUE DE CANCER 4 -- 1.2. LES VACCINS ANTI-HPV 4 -- 1.3. LA VACCINATION ANTI-HPV EN BELGIQUE . 6 -- 1.4. QUESTIONS DE RECHERCHE 7 -- 2. MORBIDITÉ ET MORTALITÉ DU HPV EN BELGIQUE. 8 -- 2.1. CANCERS LIÉS AU HPV. 8 -- 2.2. DESCRIPTION PAR TYPE DE CANCER. 10 -- 2.2.1. Cancers du col utérin 10 -- 2.2.2. Cancers de lanus 10 -- 2.2.3. Cancers de la vulve 10 -- 2.2.4. Cancers du vagin 10 -- 2.2.5. Cancers du pénis 11 -- 2.2.6. Cancers de loro-pharynx 11 -- 2.3. VERRUES ANO-GÉNITALES. 11 -- 2.4. AUTRES COMPLICATIONS DE LINFECTION PAR HPV 11 -- 2.5. DIFFÉRENCES HOMMES-FEMMES DANS LES AFFECTIONS LIÉES AU HPV 12 -- 3. EFFICACITÉ ET SÉCURITÉ DES VACCINS. 12 -- 3.1. EFFICACITÉ. 12 -- 3.2. PROTECTION CROISÉE 13 -- 3.3. DURÉE DE LA PROTECTION13 -- 3.4. SÉCURITÉ. 13 -- 3.5. EFFET INDIRECT . 14 -- 4. VACCINATION DES GARÇONS DANS DAUTRES PAYS INDUSTRIALISÉS.14 -- 5. ANALYSE ÉCONOMIQUE 16 -- 5.1. QUEL SERAIT LE RAPPORT COUT-EFFICACITE DUNE VACCINATION UNIVERSELLE (FILLES ET GARÇONS) PAR RAPPORT A LA VACCINATION DES FILLES SEULES, DANS LES « INDICATIONS EMA » ? 17 -- 5.1.1. Pour une couverture des filles similaire à celle de la Communauté flamande 17 -- 5.1.2. Pour une couverture des filles similaire à celle de la Fédération Wallonie-Bruxelles 17 -- 5.2. QUEL SERAIT LE RAPPORT COÛT-EFFICACITÉ DUNE VACCINATION UNIVERSELLE PAR RAPPORT À LA VACCINATION DES FILLES SEULES, POUR PROTÉGER CONTRE TOUTES LES AFFECTIONS LIÉES AU HPV ? . 18 -- 5.2.1. Pour une couverture des filles similaire à celle de la Communauté flamande 18 -- 5.2.2. Pour une couverture des filles similaire à celle de la Fédération Wallonie-Bruxelles 18 -- 5.3. EST-CE QUUNE AUGMENTATION DE LA COUVERTURE VACCINALE CHEZ LES FILLES -- SEULES SERAIT PLUS COÛT-EFFICACE QUE L'EXTENSION DU VACCIN AUX GARÇONS? 18 -- 5.4. SI LA VACCINATION UNIVERSELLE EST CHOISIE, QUEL SERAIT LE VACCIN LE PLUS COÛTEFFICACE ?. 19 -- 5.5. QUEL SERAIT LE RAPPORT COÛT-EFFICACITÉ DE LA VACCINATION UNIVERSELLE PAR RAPPORT À CELLE DES FILLES SEULES AVEC DES PRIX DE VACCIN BAS ? 19 -- 5.6. QUEL EST L'IMPACT DE LA DURÉE DE PROTECTION DU VACCIN SUR LE RAPPORT COÛTEFFICACITÉ ?. 19 -- 5.7. QUESTIONS AUXQUELLES CETTE ÉTUDE NA PAS PU RÉPONDRE 19 -- 6. CONCLUSION 20 Link for e-copy: https://doi.org/10.57598/R308Bs Format of e-copy: PDF (1,31 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4510 Appareils auditifs en Belgique / Claire Beguin / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
![]()
Copies
Barcode Call number Media type Location Section Status No copy Assessing the economic value of anti-cancer therapies / Niels Neymark / New York ; Berlin ; Tokyo : Springer (1998)
Assessing the economic value of anti-cancer therapies [printed text] / Niels Neymark . - New York ; Berlin ; Tokyo : Springer, 1998 . - XI, 285 p. ; 23 cm. - (Recent results in cancer research; 148) .
ISBN : 978-3-540-64030-1
Languages : English (eng)
Descriptors: Classification
QZ 266 Neoplasms. Cysts -- Therapy
Indexation
Antineoplastic Agents ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Economic Evaluation ; Health Care Costs ; NeoplasmsAbstract: BOOK REVIEW Kevin B. Knopf, JNCI, 1999, 91(14), 1248-1249
The need for accurate economic analysis to guide health care delivery is irrefutable, since health care costs continue to rise in parallel with a growing demand in value for our spending. Cancer care accounts for 5%-10% of all health care dollars spent in the United States, and although breakthroughs in cancer research will provide much needed improvements in the treatment of cancer, they will also come at a cost. Dr. Neymark speaks in his preface of the "aura of sanctity" surrounding cancer so that "everything possible" is done for the patients. This aura derives partly from the seriousness of the disease and the fear surrounding a diagnosis of cancer. However, a need for high-quality economic research in cancer care is still necessary to guide rational resource allocation, and this text succeeds in succinctly and thoughtfully summarizing the state of the art of economic analysis of cancer therapies. By exploring the literature related to economic evaluation of cancer therapies over a 10-year period, Dr. Neymark has provided a great deal of food for thought for research in this area.
The general nature of economic evaluation is defined in the introduction:
"Economic evaluation is a widely applicable economic method concerned with the comparison of two or more alternatives with respect to both their positive and negative impacts or benefits and costs, respectively, as these impacts are generally termed. It is the presence of alternative methods of treatments that create an economic problem."
It is the presence of choices that makes economic evaluation a valuable tool. In the past, the treatment of cancer, particularly metastatic disease, was limited in the number of options available, as the author notes. However, new treatments are continually being developed, which come with a cost versus benefit trade-off, and thus economic evaluations will assume a greater importance as our therapeutic choices increase.
The very brief chapter on the epidemiology of cancer could have been made more substantial, and the addition of graphs to interpret trends would have been useful. The following chapter provides an excellent overview of the nature of cancer and its major treatment modalities, which will be of interest to the nonclinician.
The chapters on economic evaluation and the economic burden of cancer are well written and serve as solid introductions for the novice to these areas and a good review for others. He describes the rationale and methods behind the cost-of-illness studies, which he treats with a healthy skepticism. A lengthy section on economic evaluation covers important concepts and describes, in turn, the four major types of studies: cost-minimization, cost-benefit, cost-effectiveness, and cost-utility, the latter two being the most appropriate type of study for most cancer therapeutics. Discussion about methodology involved in collecting data for cost and outcomes, perspective of the analysis, valuation, and presentation and interpretation of results of economic evaluations are also well written.
The heart of the text is a thorough discussion of the major economic studies of cancer treatment published from 1985 to 1996. The author reviews the relevant literature pertaining to costs and treatment of most of the major malignancies, including relevant supportive care areas. Topics covered include the following: breast cancer (14 studies), lung cancers (eight studies), colorectal cancer (eight studies), prostate cancer (10 studies), genitourinary and gynecologic malignancies (11 studies), leukemias and lymphomas (10 studies), therapies for emesis and infections (nine studies), hematologic support and transplantation (18 studies), and palliative care (five studies). Every section is preceded by an overview of treatment options that are fairly accuratealthough not without occasional omissions and errors; these sections will be invaluable for the nonclinician.
Each study is described concisely, including rationale, type of analysis, perspective, techniques, data sources, and results, when stated by the original authors. Dr. Neymark justly criticizes studies with conceptual or methodologic flaws, erroneous assumptions, or clear oversights in the evaluation, and as a critical reviewer, he certainly holds no punches. This lengthy and in-depth review of a body of work makes his text a compelling read and enables the reader to gain a great deal of insight into how to, and often how not to, evaluate the economics of cancer therapeutics. Through reading his summation of the body of literature, one obtains an appreciation of not only what studies have been performed and which studies should be performed but also a sense of the "state of the art of the methodology" currently in use. Each chapter closes with a concise table of the articles reviewed and concluding comments that highlight the strengths and weaknesses in the studies, comparing studies when appropriate, and pointing out possible future directions.
A concluding chapter discusses some of the broader controversies, which have been hinted at throughout the review, in an insightful manner. The use of "league tables" to compare cost-effectiveness ratios is justly criticized, due to the implicit assumption of comparability of studies. The issue of costs versus charges is briefly discussed, and a lengthy discussion of the merits of collecting economic data in clinical trials points to the complementary benefit of modeling. The nature of outcomes used, e.g., the inapplicability of life-years saved as an outcome to evaluate antiemetic therapies, is also explored.
By design, this review cannot serve as a complete "how to" guide for economic evaluations, although there are many pearls to be gained from a thorough reading. The economics of cancer prevention and screening, which are in many ways more difficult to study from an economic perspective, were not explored in this text, but there are other sources for this information.
Many of the reviewed studies are excellent and may serve as an aide to treatment choices for a specific situation. In a broader sense, this book will be extremely valuable for both the health service researcher who wishes to learn about cancer economics and the cancer researcher interested in the economic aspects of their field. By reviewing 9 years of the literature in a systematic, thoughtful, and critical manner, there is much to be gained for the interested reader who invests a small amount of time reading this excellent work.Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=244 Hold
Place a hold on this item
Copies (1)
Barcode Call number Media type Location Section Status 10273-00306 QZ 266/NEY Book KCE Library (10.124) Available Autologous breast reconstruction techniques after mammary resection / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
![]()
Autologous breast reconstruction techniques after mammary resection : time measurements for a potential reevaluation of the surgeon fee [printed text] / Sophie Gerkens, Author ; Stefaan Van de Sande
, Author ; Roos Leroy
, Author ; Anne-Sophie Mertens, Author ; Jonathan Schreiber, Author ; Dries Van Halewyck, Author ; Jan Bellaert, Author ; Hans Van Brabandt
, Author ; Nathalie Swartenbroekx, Author ; Caroline Obyn, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2015 . - 102 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 251) .
ISSN : D/2015/10/273/77 : 0,00
Study 2014-25_HTA_Cost_breast_reconstruction
Languages : English (eng)
Descriptors: Classification
W 74 Medical economics. Health care costs (General)
Indexation
2014-25 ; Costs and Cost Analysis ; Documents related to KCE studies ; Hospital Costs ; Mammaplasty ; Operative Time ; R251 ; Reimbursement Mechanisms ; Surgical FlapsContents note: SCIENTIFIC REPORT .9 -- 1 INTRODUCTION 9 -- 1.1 BACKGROUND AND OBJECTIVES 9 -- 1.2 RESEARCH QUESTIONS 9 -- 1.3 DESCRIPTION OF AUTOLOGOUS BREAST RECONSTRUCTION INTERVENTIONS .10 -- 1.3.1 The primary reconstruction or the flap transfer .10 -- 1.3.2 Secondary interventions 14 -- 2 THE CLINICAL EFFECTIVENESS AND SAFETY OF AUTOLOGOUS BREAST RECONSTRUCTION .15 -- 2.1 INTRODUCTION .15 -- 2.2 METHODS 15 -- 2.2.1 Literature search 15 -- 2.2.2 Quality appraisal and data extraction .16 -- 2.3 RESULTS 16 -- 2.4 GENERAL CONCLUSIONS 24 -- 3 BELGIAN PRACTICE: ANALYSES OF BELGIAN HOSPITAL ADMINISTRATIVE DATA 25 -- 3.1 INTRODUCTION .25 -- 3.1.1 Main characteristics of the data sources 25 -- 3.1.2 Cross-sectional data window .26 -- 3.2 METHODS 26 -- 3.2.1 Research questions 26 -- 3.2.2 Target interventions 27 -- 3.2.3 Selection criteria for data extractions .27 -- 3.2.4 Data extraction, transformation and loading (ETL) .27 -- 3.2.5 Checking exhaustiveness of data extraction 29 -- 3.2.6 Check marking codes and stays for breast cancer .29 -- 3.2.7 Research focus tables 29 -- 3.2.8 Grouping interventions and complications 30 -- 3.2.9 Investigating complications in administrative hospital data 31 -- 3.2.10 investigating intervention lead times 32 -- 3.2.11 Calculating fractions and ratios .32 -- 3.2.12 Health insurance costs calculations 33 -- 3.3 RESULTS 34 -- 3.3.1 General results for index interventions .34 -- 3.3.2 Complication rates 40 -- 3.3.3 Intervention lead times 44 -- 3.3.4 Fractions & ratios .45 -- 3.3.5 Health insurance costs 47 -- 3.4 LIMITATIONS AND MAIN FIGURES 51 -- 4 TIME MEASUREMENTS AND VALUATION SCENARIOS FOR THE SURGEON COST .53 -- 4.1 INTRODUCTION .53 -- 4.2 SCOPE OF THE STUDY.53 -- 4.2.1 Perspective .53 -- 4.2.2 Treatment considered: the full autologous breast reconstruction episode with flap 53 -- 4.3 TIME DRIVEN COSTING METHODOLOGY 54 -- 4.4 RECRUITMENT AND SELECTION OF THE SURGEON TEAMS 54 -- 4.4.1 Recruitment .54 -- 4.4.2 Candidates 54 -- 4.4.3 Selection 54 -- 4.4.4 Pilot teams 55 -- 4.4.5 Presentation of results 55 -- 4.5 CONSIDERED INTERVENTIONS .55 -- 4.6 THE LIST OF ACTIVITIES RELATED TO THE INTERVENTIONS 58 -- 4.6.1 Activities for the flap transfer 59 -- 4.6.2 Secondary interventions 60 -- 4.6.3 Re-interventions for complications 62 -- 4.7 CONSIDERED RESOURCES 63 -- 4.8 UNIT COSTS FOR EACH RESOURCE AND COST DRIVERS .64 -- 4.8.1 Unit cost for the work done by plastic surgeons and other resources borne by plastic surgeons 64 -- 4.8.2 The work of the surgeons-in-training .68 -- 4.8.3 The work of the tattoo nurse 69 -- 4.8.4 The work of other medical profiles 69 -- 4.8.5 Cost drivers .69 -- 4.9 DATA COLLECTION PLAN AND TEMPLATES .71 -- 4.10 DATA OVERVIEW AND DATA VALIDATION 72 -- 4.11 RESULTS 74 -- 4.11.1 Time results .74 -- 4.11.2 Cost results .83 -- 4.12 SUMMARY OF MAIN FIGURES AND HANDLING OF UNCERTAINTY 93 -- 4.12.1 Constant duration per technique for start and stop activities .93 -- 4.12.2 Variability in intervention duration and man-hours 93 -- 4.13 STUDY LIMITATIONS 97 -- 5 DISCUSSION AND CONCLUSION 98 -- REFERENCES 101 Link for e-copy: https://doi.org/10.57598/R251C Format of e-copy: PDF (1,56 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3628 Autologous breast reconstruction techniques after mammary resection / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
![]()
PermalinkAutologous breast reconstruction techniques after mammary resection / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
![]()
PermalinkDe behandeling van (chronische) lage rugpijn in een multidisciplinair pijncentrum (de) / Jan Van Zundert / Leuven [Belgium] : Katholieke Universiteit Leuven (KUL) (2001)
PermalinkBorstreconstructie na kanker / Sophie Gerkens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2015)
![]()
PermalinkChirurgie assistée par robot / Cécile Camberlin ; Arnaud Senn ; Mark Leys ; Chris De Laet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)
![]()
PermalinkCost and economic evaluation of radiotherapy / Yolande Lievens / Leuven [Belgium] : Katholieke Universiteit Leuven (KUL) (2002)
PermalinkCost-effectiveness analysis of HPV vaccination of boys in Belgium / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
![]()
PermalinkCosts and Outcomes of Chiropractic Treatment for Low Back Pain / Allan Brown / Ottawa [Canada] : Canadian Coordinating Office for Health Technology Assessment (2005)
![]()
PermalinkLe coût des prothèses dentaires / Van den Steen, Dirk / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2005)
![]()
PermalinkDrug-eluting stents for the treatment of coronary artery disease / ECRI Health Technology Assessment Information Service. / ECRI (2006)
![]()
Permalink
